A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects with Small Cell Lung Cancer (SCLC) (DeLLphi-309)

  • Arulananda, Surein (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date22/01/25 → 21/01/30